Your browser doesn't support javascript.
loading
A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.
D'Amico, Lucia; Menzel, Ulrike; Prummer, Michael; Müller, Philipp; Buchi, Mélanie; Kashyap, Abhishek; Haessler, Ulrike; Yermanos, Alexander; Gébleux, Rémy; Briendl, Manfred; Hell, Tamara; Wolter, Fabian I; Beerli, Roger R; Truxova, Iva; Radek, Spísek; Vlajnic, Tatjana; Grawunder, Ulf; Reddy, Sai; Zippelius, Alfred.
Afiliação
  • D'Amico L; Cancer Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Menzel U; Department of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland.
  • Prummer M; NEXUS Personalized Health Technologies, ETH Zürich, Switzerland and Swiss Institute of Bioinformatics, Zürich, Switzerland.
  • Müller P; Cancer Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Buchi M; Department of Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharma GmbH and Co. KG, Birkendorfer Str. 65, 88400, Biberach an der Riss, Germany.
  • Kashyap A; Cancer Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Haessler U; Cancer Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Yermanos A; Department of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland.
  • Gébleux R; Department of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland.
  • Briendl M; NBE-Therapeutics Ltd, Hochbergerstrasse 60C, 4057, Basel, Switzerland.
  • Hell T; NBE-Therapeutics Ltd, Hochbergerstrasse 60C, 4057, Basel, Switzerland.
  • Wolter FI; NBE-Therapeutics Ltd, Hochbergerstrasse 60C, 4057, Basel, Switzerland.
  • Beerli RR; NBE-Therapeutics Ltd, Hochbergerstrasse 60C, 4057, Basel, Switzerland.
  • Truxova I; Celonic AG, Eulerstrasse 55, 4051, Basel, Switzerland.
  • Radek S; NBE-Therapeutics Ltd, Hochbergerstrasse 60C, 4057, Basel, Switzerland.
  • Vlajnic T; Sotio s.a, Jankovcova 1518/2, 170 00, Prague 7, Czech Republic.
  • Grawunder U; Sotio s.a, Jankovcova 1518/2, 170 00, Prague 7, Czech Republic.
  • Reddy S; Institute of Pathology, University Hospital Basel, Basel, Switzerland.
  • Zippelius A; NBE-Therapeutics Ltd, Hochbergerstrasse 60C, 4057, Basel, Switzerland.
J Immunother Cancer ; 7(1): 16, 2019 01 21.
Article em En | MEDLINE | ID: mdl-30665463
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Receptor ErbB-2 / Imunoconjugados / Antraciclinas / Receptor de Morte Celular Programada 1 / Antineoplásicos Imunológicos / Neoplasias Mamárias Experimentais Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Receptor ErbB-2 / Imunoconjugados / Antraciclinas / Receptor de Morte Celular Programada 1 / Antineoplásicos Imunológicos / Neoplasias Mamárias Experimentais Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2019 Tipo de documento: Article